Retropharmacology of Gliptins: A Focus on Inflammatory Bowel Disease by Chandra, Srikanta et al.
Chandra et al                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1013-1018 
ISSN: 2250-1177                                                                                 [1013]                                                                                     CODEN (USA): JDDTAO 
Available online on 15.06.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                         Review Article 
Retropharmacology of Gliptins: A Focus on Inflammatory Bowel Disease 
Srikanta Chandra1*,  Avik Das2 , Jyotirmay Samanta3 , Tathagata Ray4, Lucky Mukherjee5, Bijayan Mukherjee6 
1 Gupta College of Technological Sciences, Department of Pharmacology, Asansol, West Bengal, 713301 
2 Assistant Professor of Gupta College of Technological Sciences , Department of Pharmacology , Asansol , West Bengal , 713301  
3 Assistant Professor of Genex College of Pharmaceutical Science & Technology, Department of Pharmacology, Chinsurah, West Beng al, 712102 
4 Department of Pharmaceutical Technology, JIS University, Kolkata West Bengal, 700109 
5 Bengal College of Pharmaceutical Science & Research, Durgapur, West Burdwan, West Bengal, 713212 
6 NRS Medical College, Department of General Medicine, Kolkata, Entally, West Bengal, 700014  
 
ABSTRACT 
As we know inflammatory bowel disease is an emergent plight in developed & developing countries. IBD is an idiopathic ulceroinflammatory 
condition of the bowel which may or may not have transmural stretch. IBD has two clinic pathological condition Ulcerative colitis & Crohns’s 
disease. In United State of America there are 1.4 million of people suffering from Ulcerative colitis. IBD has a plethora of comorbid disorders 
.Gastrointestinal disorder arising from cholelithiasis, cutaneous disease arising from psoriasis & metabolic disorders arising from diabetes 
mellitus. DPP4 which is instrumental in aggravating diabetes mellitus gets hiked in IBD too , which may have serious implications in the 
worsening of the latter in diabetes . Hence, in our research we probed for the anticolitic potential of a standard inhibitor of DPP4, Linagliptin to 
ensure the enzymes suitability as a probable target for IBD.  
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Introduction 
Inflammatory Bowel Disease (IBD) is looming large on the 
modern society which has raised the brows of the medical 
scientists in both the developed and developing countries . 
According to American Gastrological Society (AGS) 
Inflammatory Bowel Disease is defined as acute or chronic 
idiopathic ulceroinflammatory condition of the bowel which 
may or may not have transmural stretch .IBD has two 
encompasses pivotal kinds of pathological condition one is 
Ulcerative colitis (UC) another one is Crohn’s disease (CD) 
.Ulcerative colitis is a chronic ulceroinflammatory condition 
primarily confined within colonic mucosa with variable 
distortion of the colonic architecture .Where as Crohn’s 
disease (CD) is a chronic ulceroinflammatory condition 
analogues to ulcerative colitis but having a transmural 
infestation . Epidemiologically  IBD has greater prevalence in 
the global prospective .So we decided to zero in on IBD in our 
work ahead . As suggested in the literature the course of the 
IBD  is often complicated due to the multifactorial etiology 
under pinning the condition which demands closer overview 
. The pivotal contours may be featured astoxic megacolon , 
pseudopolyps and backwash ileitis .  The featured 
encountered in the clinical course of the disease are 
multiferrous spanning from rectal bleeding , weight loss 
abdominal pain and malaise 1. Coming to the option available 
for management they include both non pharmacological 
aspects and pharmacological aspects . Under non 
pharmacological aspects life style changes like monitored 
dieting , exercise plays a desire role in the therapy and 
psychological intervention also deployed to control the 
functional aspects of the disease . On the other hand 
Salfasalazine and Infliximab are still considered as a corner 
stone of the therapy as per as pharmacological aspects .2 So a 
through search  of available literature are also brought 
forward an important aspects which still now has remain 
largely on the flanked. IBD as can be conjured up is also 
associated with a plethora of comorbid disorders which 
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includes gastrointestinal disorders arising from cholilethiasis 
, cutaneous disease like psoriasis and metabolic disorders 
like diabetes mellitus . Since , Salfasalazine , Balsalazide , 
Infliximab  are having a limitation such as hypersentivity 
reaction ,  adrenal suppression  , nausea , vomiting , 
weakness etc3  .Hence , we found a good rational behind 
probing for the anticolitic potential in our pipeline drugs 
that’s  gliptins .  
Epidemiology  
There is wide variation between the incidence rates of 
inflammatory bowel disease (IBD) .  In Europe country 
incidence rates range from 4.1/100,000 (Romania) to 
81.5/100.000 .In Asia and the middle east incidence was 
lower 0.1-6.3/100.000. On the other hand USA the incidence 
is having intermediates rates ranging from 0 to 19.2/100.000 
population. However, currently in Sweden 61,000 patients 
are suffering from Inflammatory Bowel Disease(IBD) .  In 
Brazil an epidemiological study conducted by the Botucatu 
Medical School evaluated the incidence and prevalence of 
Inflammatory bowel disease in micro region of Sao Paulo 
State. Since , in India the first such study was conducted by 
Khosla et al., in the year of 1984 at Haryana in North India4. 
The study included 21,971 participants and noted a 
prevalence of 42.8 Ulcerative colitis (UC) patients. The next 
study which is conducted in 15 years later by Sood et al., 
from Punjab . However, incidence was calculated after 1 year 
later and was reported to be 6.02/100.000 . The crude  
overall incidence of Inflammatory bowel disease (IBD) , 
Ulcerative colitis (UC)  and Crohn’s disease(CD)   from Asia 
was 1.37,0.76 and 0.54 per 100.000 where as in Australia it 
was 23.67,7.33 and 14.00 respectively  bin . Data from 
western Asia including studies from Kuwait , Turkey and 
Israel  revealed an incidence rate of 2.8/100.000  and 
5.04/100.000 in Kuwait and Israel respectively bin.5 
However , the prevalence of 4.9/ 100.000 and 167/100.000  
in Turkey and Israel respectively bin. The prevalence of 
Crohn’s disease (CD)  in japan appears to have risen very 
rapidly from 2.9/100.000 individually in the year of 1986 to 
13.5/ 100.000 . quadrupled from 7.57 /100.000 individually 
in 1997 to 30.87/100.000 individuals in 2005.Over a period 
of 9 years the prevalence of Ulcerative colitis  in Hong kong 
nearly tripled from 2.36/100,000 individuals  in 1997 to 
6.30/100,000  individuals in 2006. Crohn’s disease 
prevalence in Singapore also increased markedly from 
1.3/100,000 individuals in 1990 to 7.2 /100,000 individuals 
in2004.The geographical variation is more common for 
inflammatory bowel disease (IBD) . However , in Sweden and 
Netherlands pediatric patients who are suffering from 
Ulcerative colitis that is more common rather than Crohn’s 
disease (CD) .Since , the most instrumental point is that 
Crohn’s disease become more active rather than Ulcerative 
colitis  in Sweden. In Scotland Crohn’s disease is not 
unknown rather than England . In Asian countries  specially 
in India subcontinent the shadow of inflammation bowel 
disease (IBD)  is looming large on the society through the 
recent past. Crohn’s disease may shown  below the age of 20-
25 years varies between 25-40 % it also affect both sex boys 
and girls .6 In South Indian boys  are more effected on 
Crohn’s disease rather than South  Indian girls.  Most studies 
reporting the incidence of CD (3/5) were from the United 
Kingdom ,with a predominant  SA migrant group . The 
remaining  two studies from Canada described the SA 
paediatric  population  and one study compared non –
immigrants to SA . The incidence of CD in SAs was  
consistently lower than Caucasian ,except for one Canadian 
paediatric study .The Benchimol study showed a lower 
incidence in SA compared to other groups within the same 
environment .The two United Kingdom studies where the 
incidence was examined over two time periods showed an 
increase in the incidence of CD in the SA population ,from 1.2 
to 2.3/100000 in East London  and 1.2 to 3.1/100000 in 
Leicester .The last migrant United Kingdom incidence studies 
were published in 1989.7 
Pathophysiology of Inflammatory Bowel Disease 
(IBD): A General Overview 
Epidemiologically ulcerative colitis (UC)  has a greater 
prevalence in the global prospective . so , we decided to zero 
in on ulcerative colitis in our work ahead. As suggested in the 
literature the course of ulcerative colitis is often complicated 
due to the multifactorial etiology under pinning the 
conditions which demands closer overview The pivotal 
contours may be featured as toxic megacolon , pseudopolyps 
, and backwash iletis.  .Toxic megacolon evolve from the 
stalling of the fecal movement of the colonic lumen due to the 
spasticity arising from the wide spread neural  damage in the 
region associated with microbial over growth . However, in 
ulcerative colitis there is wide spread destruction of the 
luminal wall which leads to formation epithelium bulges 
obstructing the lumen these are commonly termed as 
pseudopolyps . On the other hands a common featured 
essentially associated with pancolitis in which the lesions 
spread beyond the confinds of ileocecum junction this is 
known as backwash ileitis.8 Inflammatory  bowel disease 
(IBD) is a multifactorial disorder  characterized by chronic 
inflammation of the intestine . Since the pivotal point is that 
disturbance of the immune system or imbalanced 
interactions with microbes leads to amelioration of chronic 
intestinal inflammation.Th1 cells play a role in the 
pathogenesis of Inflammatory bowel disease (IBD)  is related 
to chrocity of intestinal inflammation where as Th2 cells play 
a role  in the pathogenesis of Crohn’s disease (CD)  However, 
after activation of Th17 / regulatory T (Treg cells)  are 
pivotal component which is helped to build up intestinal 
inflammation. Since , Tumor necrosis factor( TNF)  are plays  
a  instrumental role to identify the pathogenesis of 
Inflammatory bowel disease (IBD) .9 The intestinal 
epithelium cells contains different types  of cells namely 
enterocyte , goblet cell , neuroendocrine cell , M cell or 
mother cell and epithelium resident intestinal stem cells. 
These cell structurally constitute crypts and villi . A single 
columnar cell lining with a tight junction and secrete mucus 
containing antimicrobial peptides, to protect  mucosa , a 
mucus layer is present which is covered by epithelial surface 
. However, this epithelium mucus layer is composed of 
glycosaylated mucin, mucin from goblet cells . Since , mucin 
is encoded by Muc 2. However, genetic factors plays a role so 
here  mutation of NOD2 gene is a instrumental point  in the 
pathogenesis of inflammatory bowel disease (IBD) .10 The 
intestinal epithelium which is a pivotal part of the innate 
immune system and play a role in the maintenance of 
mucosal homeostasis. Epithelium cells are very tight and 
highly selective between periphery and intraluminal 
microenvironment .  Briefly , the chief determinant of the 
course of pathology include intestinal microbiota , intestinal 
epithelium dysfunction and aberrant mucosal immune 
response . However, chromosome 5 containing SLC222A4 
and SLC22A5 also shows some aberrations in patients 
suffering from Crohn’s disease (CD) .11In the modern era 
microbial profiles at various stages of colitis have been  
described and characterized that depend on the time and 
area  within the gastrointestinal tract. It is not yet entirely 
clear whether   changes in the composition of the microbiota 
are  the cause or consequence of inflammatory process in the 
intestinal tissue. Since , the most consistent change observed 
among the vast   majority of inflammatory bowel disease 
(IBD)  patients is a decrease  in intestinal microbiota 
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diversity , with slightly different findings between ulcerative 
colitis (UC) and Crohn’s disease ( CD) patients .Since , in 
Crohn’s disease ( CD) a decrease in  Formicates  is often 
observed  , including butyrate –producing bacteria namely 
Faecalibacterium  prausnitzii . This leads to over production  
of proinflammatory cytokines and downstream events. In 
Ulcerative colitis (UC) , several  other groups  of bacteria 
besides  butyrate producing  Firmicutes are often reduced , 
including  Bacteriodes and Clostridium genera 12.  On the 
other hand , Enterococcus and Gamma proteo bacteria  are  
found in higher  amounts in fecal  samples from Ulcerative 
colitis (UC)  patients .Although the interaction between the 
host and intestinal microbiota  seen to plays a crucial  role in 
the pathogenesis of inflammatory bowel disease (IBD) .Since 
, a significant amount of IBD patients  do not achieve clinical 
remission after conventional therapy , there is legitimate 
need for new  therapeutic approaches  
Treatment of Inflammatory Bowel Disease (IBD) & 
Emerging Challenges: 
Inflammatory bowel disease ( IBD) is looming large on the 
modern society which has raised the brows of the medical 
scientists in both the developed and developing countries. 
IBD has two clinicopathological condition Ulcerative colitis & 
Crohn’s disease .Coming to the option available for 
management they include both non pharmacology aspects 
and pharmacology aspects . Under the non-pharmacological 
aspects lifestyle changes like monitored dieting and exercise 
may play a desire role in the therapy and psychological 
intervention also  a deployed to control the functional 
aspects of the disease. On the other hand sulfasalazine and 
mesalamine are still considered  as  corner stone of the 
therapy as per as pharmacological aspects are concern they 
may be deployed   as step up and top down schedule. 
However, mesalamine is still the preferred one because of 
better side effect profile. Salfasalazine have play a role in the 
treatment of inflammatory bowel disease . This prototype 
drugs are contain mesalamine and sulfapyridine moieties. 
However  , Mesalamine having an active site in colon show 
the effectiveness in the distal ileum. On the other hand in the 
modern era 45% patients are taken salfasalazine but pivotal 
point is that it shows emergent nuance namely 
hypersensitivity reaction. Dose related adverse effects are 
nausea , vomiting  , headache . However, bone marrow 
suppression and hepatitis are very common nuance of 
Salfasalazine . In the modern days steroidal drugs play a role 
in the treatment of inflammatory bowel disease . 
Corticosteroids are used as a step up therapy in the 
treatment of inflammatory bowel disease . However , 
Corticosteroids are associated with different types of adverse 
effect namely  adrenal suppression , fluid retention and 
another one is hypertension . According to National Institute 
of Health they have been developed methyl Prednisolone 
acetate at a dose of 5 mg per day . However, using of methyl 
prednisolone acetate  having common nuance it suppress the 
bone . Calcium supplementation is needed at a dose of 1000-
1500 mg/day body weight  where as vitamine D is used at a 
dose of 800 units per day. Few year laters different types of 
immunomodulators are used  namely  Azathioprine  and its 
derivative Marcaptopurine.13   However, these drugs shows 
different types of adverse effects namely  nausea , vomiting  , 
leucopenia , and pancreatitis. However, Toclizumab is a 
monoclonal antibody which is blocked IL-6 receptors and  
has been approved for  rheumatoid arthritis . IL-6   along 
with TGF- β   increases the production of  IL-17  producing T 
helper cells which is inhibit  differentiation of regulatory T 
cells. This imbalance of T helper 17 cells to regulatory T cells 
can leads to immunogenic intolerance  and its ameliorates 
different types of  immune mediated conditions. ( 
Toclizumab is associated with inflammatory bowel disease  
but now a days it arising different types of adverse effects 
namely headache , nausea , hypersensitivity reaction .14  
Since , thiopurines plays a putative role in the treatment of 
inflammatory bowel disease (IBD) .   A plethora of anti TNF  
antibodies are available  namely  Adalizumab ,  Cetolizumab ,  
Golimumab .Infliximab  is a chimeric  mouse – human 
monoclonal antibody  directed specifically  to TNF. It was  
ameliorates as a therapeutic agent  for immune mediated 
diseases  and in IBD it is recently  used chiefly  in the 
treatment of Crohn’s disease and Ulcerative colitis . 
Infliximab also has  beneficial effects in the healing of fistulas  
in Crohn’s disease . Since , the mechanism of action of 
Infliximab  involves its binding  to both soluble  and 
membrane bound TNF  ,with subsequently inhibition  of the 
biological activity of this  cytokine .It should be administered  
intravenously   at a dose of 5 mg/kg  and variable dosing 
schedule .However , Infliximab  is having some limitation . It 
is associated with  acute infusion and delay infusion . Briefly 
acute infusion  reactions can have  symptoms   including 
flushing , headache , dizziness , chest discomfort 15.On the 
other hand  delayed infusion reaction which are type III 
immune complex –mediated reaction  are associated with 
joint pain , rash  and fatigue . Azathioprine and 6 –
marcaptopurines are two most commonly used thiopurine 
compounds in inflammatory bowel disease (IBD) in 
management . Because of their slow onset , requiring at least 
12-17 weeks of continuous therapy  to produce noticeable 
effect. Briefly , thiopurines have a specific role in 
inflammatory bowel disease (IBD)  i.e one of maintaining 
long term remission . The recommended dose is 1.5-2.5 mg 
/kg   for azathioprine and 0.75 -1.5 mg /kg for 6 
Mercaptopurine . Since , common side effects associated with 
Thiopurines are leucopenia , hepatotoxicity , pancreatitis and 
gastric intolerance .  A full blood count and liver function test 
should be conducted before starting a thiopurine and 
continued every 2 weeks for the first 2 months .16  
Comorbidities Associated with Inflammatory 
Bowel Disease: A Brief Overview  
Ulcerative colitis is a plethora of comorbid disorder namely 
gastrointestinal disorder arising from cholelithiasis , 
cutaneous disease like psoriasis , metabolic disorder like 
diabetes mellitus. Psoriasis is a chronic hyperproliferative 
immune mediated inflammatory skin disease. However, 1-
3% population suffered from this disease  . Pathophysiology 
of psoriasis having different factors are include namely 
genetic predisposition  another pivotal point is that  
environmental factors which are associated with skin disease 
. However, different types of immune mediated facts are 
responsible for pathology of psoriasis . On the other hand T 
cell or helper T cell play a role in the pathology of psoriasis. 
Cytokine , denditric  presenting cell they are play a role in the 
pathology of psoriasis. Since , the top most factors are that 
TH1, TH17 , TNF alpha , IFN gama , IL 17 , IL 22 they are play 
a major role in the pathology of psoriasis .17 
Inflammatory bowel disease (IBD) is a group of clinic 
pathological condition of the gastro intestinal tract . 
Ulcerative colitis is associated with cardiovascular disorder 
namely hypertension.  Cardiovascular is one of the main 
reason of death  in developing countries and its prevalence is 
increase with age. The impact of Cardiovascular disorder on 
Inflammatory and  bowel disease is the same as  for the 
general population, increase complication and remaining a 
common cause of mortality. Venous thrombolism ( VTE)  
which is a common manifestation now a days and it is 
directly associated with inflammatory bowel disease( IBD) . 
Atherosclerosis is a common  phenomenon in several 
immune based inflammatory disease particularly 
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rheumatoid arthritis and systemic vascular system are well 
known . However, different types of adverse effects are 
shows like hypertension, hyperglycemia , hyperinsulinemia 
and hyperlipidemia . However rheumatoid arthiritis, 
inflammatory activity control can reduce cardiovascular 
complications. Aminosalicylates reduce platelet activation 
whereas azathioprine inhibitis formation of platelet –
leukocyte aggregate.18 
Ulcerative colitis is an emergent plight in developed and 
developing countries. Ulcerative colitis is a chronic 
ulceroinflammatory condition of the bowel primarily 
confined with colonic mucosa with variable distortion of the 
colonic architecture. Ulcerative colitis is associated with 
cholelithiasis or gall bladder stone or intrahepatic stone or 
common bile duct stone. However, the reason of association 
between ulcerative colitis and cholelithiasis are leads to 
cholecystitis , cholangitis , pancreatitis.19  
Inflammatory bowel disease ( IBD) is a group of 
inflammatory intestinal disorders comprising two types of 
disease : Ulcerative colitis another one is Crohn’s disease . 
Ulcerative colitis is a chronic ulceroinflammatory condition 
primarily confined within colonic mucosa with variable 
distortion of the colonic architecture. Since , inflammatory 
bowel disease is associated with peripheral artery disease 
(PAD) . Traditionally, the incidence of this disease is 
relatively stable in Western countries; however the IBD  
incidence has been increasing in Asian countries  in the past 
few years. Peripheral arterial disease ( PAD) is the narrowing 
of arteries other than those that supply blood to brain or 
heart , causing a considerable burden on health care  systems 
worldwide . The prevalence of peripheral vascular disease in 
the general population is 12 % to 14% , affecting upto  20 % 
of people > 70 years . According to the Taiwan National 
Health Insurance ( NHI) data analysis, the incidence  of 
invasive PAD treatment is increasing. Traditional risk factors 
for PAD are an older age, male sex , hypertension , diabetes , 
hyperlipidemia , obesity , smoking and family history of 
vascular disease. 20 
Association Inflammatory Bowel Disease and 
Diabetes Mellitus: A Brief Overview  
Inflammatory bowel disease (IBD) is a  emergent plight  as in 
the modern era.  According to American Gastrological Society 
Inflammatory bowel disease is an acute or chronic idiopathic 
ulceroinflammatory condition of the bowel which may or 
may not have a transmural stretch. Inflammatory bowel 
disease encompasses two pivotal kinds of pathological 
condition one is ulcerative colitis( UC) another one is crohn’s 
disease . Ulcerative colitis is a chronic ulceroinflammatory 
condition of the bowel primarily confined within colonic 
mucosa with variable distortion of the colonic architecture. 
However,  the featured encountered in the clinical course of 
the disease are multiferous   spanning  from rectal bleeding , 
abdominal pain , weight loss and malaise .Inflammatory 
bowel disease are associated with diabetes mellitus .They are 
multifactorial association , interventional aggrevession and 
shared complication. Various factors link diabetes 
comorbidity to ulcerative colitis .They may range from loss of 
metabolic homeostasis leading to a disarray in intestinal 
microflora and risk of altered responses in the gut brain axis 
due to several associated complication. Interventional 
aggrevession is also common as evident from precipitation of 
hyperglycemia due to chronic use of corticosteroids in 
inflammatory bowel disease patients and adding to this are 
the varieties of shared complications prevalent in this 
patients which may manifest as neurological hepatobiliary , 
osterioarticular and vascular symptoms.21 
Role of Incretins in Modulating Inflammatory 
Bowel Disease 
Inflammatory bowel disease  is an incurable chronic 
inflammatory intestinal disorder of the gastrointestinal tract  
that dramatically  impacts quality of life .According to 
American  Gastrological Society ( AGS) inflammatory bowel  
disease  (IBD) is defined as an acute  or chronic idiopathic 
ulceroinflammatory condition of the bowel which may or 
may not have transmural stretch. Inflammatory bowel 
disease(IBD) encompasses two pivotal kinds of pathological 
condition namely ulcerative colitis (UC) and another  one is 
crohn’s disease ( CD) . Ulcerative colitis(UC) is a chronic 
ulceroinflammatory condition primarily confined with an 
colonic mucosa with variable distortion of the colonic 
architecture. Since Ulcerative colitis (UC) is 
epidemiologically associated with diabetes mellitus  ( DM) .  
Briefly, incretin  is a metabolic hormone  secreted from the 
pancreatic beta cell islet of langerhence  .  However , incretin 
mimetic and DPP4 inhibitors first introduced in the year of 
2005  as an antidiabetic agents . After few year 2007  
sitagliptin was discovered .   Glucagon like peptide 1 ( GLP-1)  
have a function through binding to GLP 1 receptor  and is 
involved in the amelioration  and progression of different 
types of disease.  Since , GLP-1 receptor  is widely expressed 
in many organs  and tissue including gastrointestinal tract , 
heart , central nervous system endocrine pancreas.  However 
, in the modern days GLP-1  has a predominant role in the 
pathogenesis of type 2 diabetes mellitus.22 Type 2 diabetes is 
a  complex metabolic disorder characterized by 
hyperglycemia  arising from a combination of insufficient 
insulin secretion  together with resistance to insulin action.  
However two most recently approved classes of therapeutic 
agents  for the treatment of  type 2 diabetes , glucagon like 
peptide-1 receptor agonists and DPP4 inhibitors  exert their 
action through  potentiation of incretin  receptor signaling . 
Incretins are gut derived hormones , principally  GLP-1 and  
glucose depedent insulinotropic peptide that are secreted  at 
low basal levels in the fasting state.  Ulcerative colitis 
patients with colectomy  showed a slower release of GLP-1  
in response to intake of glucose.  Consistently , postprandial  
GLP-1 response was also impaired in patients  with 
ileostomy  . It was unknown  wheather the colectomy  or 
inflammatory  state affects the GLP -1 release in IBD.  
However , GLP- lr  m RNA   levels was reduced  in which 
promotes mucosal epithelium restoration in a self repair 
mechanism .23  The close associations of diabetes with 
ulcerative colitis and a dearth of effective medications 
against these two conditions  prompted us to look for a 
common solution which can address these two shared 
pathologies conveniently . In the process we narrowed in on   
an emergent group of antidiabetic drugs conceptualized in 
1902 . Two major incretin based hormone  GLP and GIP   
originate from the gut  and can promote pancreatic beta cell 
growth along their enterohepatic effect beside therapeutic 
convergence leading to better efficacy . This mode of therapy 
can serve as an efficacious mean to circumvent the spectra of 
hypoglycemia  a common menace in diabetic therapy.24 
However , IBD is relevantly associated with metabolic 
disorders like diabetes mellitus epidemiologically . Behind 
the epidemiological relevance there are some technical 
reasons . Dipeptidyl peptidase is an enzyme which binds to 
its substrates namely GLP  and GIP  . Both of these are potent 
incretins .Among these GLP can be further subclassified into 
GLP1 and GLP 2 .While  GLP 1 is reported to be involved in 
hyperglycemic control , GLP 2 has  been documented  as  a 
potent enterotrophic agent . Being incretins ,both  GLPs and 
GIP  are vulnerable to cleavage by  dipeptidyl peptidases( 
DPP4 group of enzymes) which make these important 
physiological peptides short lived. Dearth of trophic peptides 
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at times of acute and chronic injury, halts the local repair 
mechanisms which promotes the progression of 
inflammatory damage in IBD patients  expressed .  Hence 
,therapies aimed at boosting GLP2 can be a  newer strategy 
in the treatment of  IBD.25  
Gliptins: Focus on Anticolitic Potential  
Inflammatory bowel disease  denotes a group of  disorders 
characterized by chronic intestinal  inflammation , the 
aetiology is unknown . Inflammatory bowel disease 
encompasses two pivotal kinds of pathological condition one 
is ulcerative colitis (UC)  and another one is Crohn’s disease( 
CD) . Ulcerative colitis is a chronic idiopathic 
ulceroinflammatory condition of the bowel primarily 
confined within colonic mucosa with variable distortion of 
the colonic architecture. Since,  Ulcerative colitis(UC)  is 
associated with diabetes mellitus (DM) .  Since , different 
types of gliptins are reported  namely sitagliptin , vildagliptin 
, Tenligliptin , saxagliptin etc . for treatment of diabtes 
mellitus (DM) .26   Gliptins inhibit the dipeptidyl peptidase 4 
(DPP4) as a results insulin secretion is increased where as 
glucagon released is decreased  that’s why blood glucose 
levels are decreased . Since gliptins are having different  
advantages briefly , Glucagon like peptidase (GLP)  and 
Gastro intestinal polypeptide (GIP)  or insulin trophic 
peptide or glucose dependent insulin trophic peptide both 
are enzymes secreted from small intestine. They looks like a 
agonist but they acts as an antagonist .  When ligand bind to 
the glucagon like receptors then ligand blocks GLP and GLP  
that’s why glucagon release is decreased and insulin 
secretion is increased  as a result blood glucose levels are 
maintained . Randomized control trial reported that 
Setagliptin and Vildagliptin having a anti inflammatory 
potential . However , Sitagliptin are not free from clinical 
contraindication.  Sitagliptin is the first generation DPP4 
inhibitor for the treatment of type2 diabetes mellitus. 
Sitagliptin acts by inhibiting  DPP4 enzyme increase the 
levels of incretins , mainly Glucagon like peptide -1 ( GLP1) . 
However , GLP 1 has a  very short half life 1-2 min  and is 
metabolized quickly by DPP4 enzyme . GLP is produced by 
intestinal L cells , which augments glucose dependent- 
insulin secretion , during the phase of nutrient absorption 
from gastrointestinal tract( GIT)  . Sitagliptin is the 
forerunner in this arena. However the drug is associated 
with the occurance of a plethora of  side effects like upper 
respiratory tract infection , nasopharyngitis and headache to 
name a few. Vildagliptin is the second DPP4 inhibitor and is 
indicated for the control of hyperglycemia in patients with 
type 2 diabetes mellitus . Vildagliptin produces sustained 
inhibition of DPP4  and produce moderate increase in GLP1 
and GIP.  Teneligliptin is the third generation Gliptin which 
offers a pharmacodynamic advantage with unique J shaped 
anchor locked domain which signifies  for its potent and long 
duration of action . Inflammatory bowel disease having a 
plethora of comorbid disorders  such as gastrointestinal 
disorders arising from cholelithiasis , cutaneous disease like 
psoriasis 27 
Antioxidant potential of gliptins: 
Dipeptidyl peptidase inhibitors, a promising group of 
antihyperglycemic drugs , inhibits the enzyme , DPP-4 , that 
destroy  GLP-1 and GIP  thereby increase  the levels as a 
result by which  blood glucose level fall.  Antioxidant 
property  is an essential mechanisms by which it reduces 
oxidative stress  in diabetic patients  there by preventing  
beta cell damage  and occurance of microvascular and  
macrovascular complications. The in vitro antioxidant 
potential of gliptins has  been proved by the work of Aparna 
et al. in 2015 . The antioxidant potential of gliptins have also 
been hinted in the work of other workers  (Puja Das et al 
.2017) who have unequivocally  opined that the gliptins may 
give protections against oxidative damage by triggering  the 
expression of certain genes which boosts  antioxidant 
reserve in the body .The gamut of therapeutic effects shown 
by gliptins have largely been attributed to its antioxidant 
potential by multiple authors . For example  kramar et al 
have found a correlation between antidiabetic activity of 
Sitagliptin with its  antioxidant potential . The anti-
inflammatory potential of Vildagliptin has been largely 
attributed to the antioxidant mechanism elicited by it . Hence 
, the inflammatory bowel disease which like any other 
inflammatory  pathology  has got an oxidative component is 
expected to show improvements due to the antioxidant 
component of gliptins .28  
Conclusion: 
Inflammatory bowel disease is an emergent nuance in 
developed and developing countries . IBD is associated with 
a plethora comorbid disorders.  Gliptins plays a putative role 
in the amelioration of inflammatory bowel disease. 
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